top of page
Browse by category
Search
Tirzepatide may only temporarily suppress ‘food noise’
A brain-computer interface reveals the tirzepatide has a short-term or incomplete effect on related brain activity in a patient with obesity, calling for further study, a study by University of Pennsylvania School of Medicine has found. The nucleus accumbens on a brain CT of a patient (Credit: Penn Medicine) The research suggests that the medication, a glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, may be able to treat
Cochrane reviews find GLP-1 drugs effective for weight loss, but more independent studies needed
Three new Cochrane reviews find evidence that GLP-1 drugs result in clinically meaningful weight loss, but industry-funded studies raise questions. The reviews were commissioned by the World Health Organization (WHO) to inform upcoming guidelines on the use of these drugs to treat obesity. The reviews, which examine the effects of three weight loss drugs known as GLP-1 receptor antagonists, have found that all three drugs result in clinically meaningful weight loss compared w
Tirzepatide plus menopause hormone therapy aids weight loss
Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with overweight...
Tirzepatide reduced the risk of developing T2Dm by 94% in adults with pre-diabetes and obesity or overweight
Eli Lilly and Company has announced positive topline results from the SURMOUNT-1 three-year study (176-week treatment period) evaluating...
WHO issues warning on falsified medicines as Lilly warns patients about counterfeit and compounded medicines
The World Health Organization (WHO) has issued a medical product alert on falsified semaglutides, the type of medicines that are used for...
Scottish Medicines Consortium accepts tirzepatide (Mounjaro) for obesity in eligible adults
The Scottish Medicines Consortium (SMC) has accepted Eli Lilly and Company’s tirzepatide (Mounjaro) for restricted use within NHS...
Tirzepatide was superior to placebo for MASH resolution
Results from Eli Lilly and Company’s SYNERGY-NASH that evaluated the investigational use of tirzepatide in adults with biopsy-proven...
Tirzepatide effective even for those with diabetes and other complications
Having medical conditions linked to obesity does not impact the total weight loss achieved with the anti-obesity medication tirzepatide,...
Tirzepatide found to reduce body weight regardless of duration of condition and BMI before treatment
Two studies presented at this year's European Congress on Obesity in Venice, Italy, have reported that tirzepatide consistently reduces...
Tirzepatide reduced sleep apnoea severity by up to nearly two-thirds in adults living with OSA and obesity
Eli Lilly and Company has announced positive topline results from the SURMOUNT-OSA phase 3 clinical trials that showed tirzepatide...
Browse by tag
bottom of page